Rescue Treatment with Infliximab for a Bilateral, Severe, Sight Threatening Frosted Branch Angiitis Associated with Concomitant Acute Onset of Presumed Dermatomyositis.
Biologics
dermatomyositis
frosted branch angiitis
immunesuppression
panuveitis
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
medline:
5
5
2023
pubmed:
9
4
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
To report a severe bilateral frosted branch angiitis associated with acute onset of systemic dermatomyositis. History and clinical examination, laboratory evaluation, fundus' and skin's color pictures, fluorescein angiography (FA), optical coherence tomography (OCT). A 32-year-old female was referred for a bilateral frosted branch angiitis and vitreitis, with skin rash, muscle pain, weakness, severe headache, compatible with dermatomyositis. After an initial improvement following an aggressive treatment by systemic steroids and mycophenolate mofetil, she was switched to intravenous infliximab (RemicadeTM, Janssen Biotech, Inc. USA) due to lack of efficacy. Nine months later, her visual acuity was improved up to 20/20 in OU, with both retinal vasculitis and vitreitis being solved. Dermatomyositis is a severe multiorgan disease which might severely involve eye structures. Anti-TNF-Alpha agents, particularly Infliximab, might offer a rapid control and long-term remission.
Identifiants
pubmed: 35394851
doi: 10.1080/09273948.2022.2057333
doi:
Substances chimiques
Infliximab
B72HH48FLU
Tumor Necrosis Factor Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM